title: Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
abstract: OBJECTIVE
  Serum CA-125, an ovarian tumor marker, is used especially in the follow-up of ovarian cancer for monitoring the efficacy of therapy and for early detection of recurrence. A number of benign gynecologic as well as benign and malignant nongynecologic conditions are associated with elevated serum CA-125 levels. Malignant and nonmalignant serosal fluids were also found to be associated with high serum levels of CA-125, suggesting that the presence of fluid in the serosal cavities may stimulate its release.
  
  
  METHODS
  We performed a clinical study in 39 patients (21 females, 18 males) on chronic hemodialysis who were divided into two groups based on the presence of fluid in the serosal cavities (peritoneum, pleura, or pericardium) without clinical and radiologic evidence of neoplasia. There were 26 patients (16 females, 10 males) aged 50.11 +/- 13.86 years (range, 20-76 years) in the serosal fluid-negative group (group 1) and 13 patients (8 females, 5 males) aged 45.30 +/- 18.84 years (range, 17-73 years) in the serosal fluid-positive group (group 2). The control group consisted of 52 healthy volunteers (30 females, 22 males) aged 44.19 +/- 12.59 years (range, 19-68 years).
  
  
  RESULTS
  Significantly elevated serum CA-125 levels were found in hemodialysis patients with serosal fluid (P < 0.05) when compared with both the hemodialysis patients without serosal fluid and the control group. There was no statistically significant difference between the control group and the patients without serosal fluids (P > 0.05).
  
  
  CONCLUSIONS
  Although CA-125 can be considered a reliable tumor marker in patients undergoing hemodialysis, it should be interpreted with caution in patients with serosal fluids.
authors.affiliation: Department of Internal Medicine, Turgut Ozal Medical Center, School of Medicine, Inonu University, Malatya, TR-44069, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Sevinc
authors.forename: S
authors.initials: S
authors.lastname: Buyukberber
authors.forename: R
authors.initials: R
authors.lastname: Sari
authors.forename: Y
authors.initials: Y
authors.lastname: Kiroglu
authors.forename: H M
authors.initials: HM
authors.lastname: Turk
authors.forename: M
authors.initials: M
authors.lastname: Ates
mesh_terms: D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy; D010490:Pericardial Effusion / Q000276:immunology; D010996:Pleural Effusion / Q000276:immunology; D006435:Renal Dialysis; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen